Baird reiterates an 'Outperform' on Amgen (AMGN); Full Dmab '147 Data About Everything We Had Hoped For

Baird reiterates an 'Outperform' on Amgen (NASDAQ: AMGN), PT $67.

Baird analyst says, "Incrementally positive on AMGN shares following full Dmab '147 bone-met prevention data presented at AUA. On balance, we view today's update as positive for Dmab, and supportive of meaningful near-term off-label use in the prevention setting. Combined with our recent survey data showing XGEVA is off to a strong start in SREs, we are increasingly confident in upside to numbers this year. Remain buyers."

For more ratings news on Amgen click here and for the rating history of Amgen click here.

Shares of Amgen closed at $59.86 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Amgen (AMGN) PT Raised to $388 at Guggenheim
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)